Endocrine Pharmacology — MCQs

A 57-year-old lady presents with chief complaints of fatigue and a 5 kg weight gain in one month. She has a 10-year history of well-controlled hypothyroidism treated with L-thyroxine. Recently, she was started on an anti-arrhythmic drug for a cardiac condition, and her symptoms began after its initiation. What is the most likely anti-arrhythmic drug she was prescribed?

Q90Medium

Which Dipeptidyl Peptidase-4 (DPP4) inhibitor requires dose reduction in both liver and kidney failure?

Endocrine Pharmacology Indian Medical PG Practice Questions and MCQs

Question 81: Which of the following is NOT a side effect of insulin?

A. Edema
B. Albuminuria (Correct Answer)
C. Hypoglycemia
D. Lipodystrophy

Explanation: **Explanation:** **Albuminuria** is the correct answer because it is not a side effect of insulin; rather, it is a clinical marker of **Diabetic Nephropathy** (a complication of the disease itself). Insulin therapy is actually used to achieve glycemic control, which helps prevent or slow the progression of albuminuria. **Analysis of Options:** * **A. Edema:** Insulin causes renal sodium reabsorption in the distal tubules. In some patients, initiating insulin therapy leads to "Insulin Edema" due to salt and water retention. * **C. Hypoglycemia:** This is the **most common** and most serious side effect of insulin therapy, occurring due to an overdose, delayed meals, or excessive physical activity. * **D. Lipodystrophy:** This occurs at the site of injection. It can manifest as **Lipoatrophy** (immune-mediated loss of fat, rarer with human insulin) or **Lipohypertrophy** (fat accumulation due to the anabolic effects of insulin, often caused by failing to rotate injection sites). **High-Yield NEET-PG Pearls:** 1. **Weight Gain:** Insulin is an anabolic hormone; weight gain is a very common side effect. 2. **Hypokalemia:** Insulin shifts potassium into cells by activating the Na+/K+ ATPase pump. This is why it is used in the emergency management of hyperkalemia. 3. **Somogyi Effect:** Post-hypoglycemic hyperglycemia caused by a counter-regulatory hormonal surge (epinephrine, glucagon) in response to late-night hypoglycemia. 4. **Injection Sites:** Absorption is fastest in the abdomen, followed by the arms, thighs, and buttocks.

Question 82: Which of the following is NOT a testosterone inhibitor?

A. Spironolactone
B. Flutamide
C. Finasteride
D. Sildenafil (Correct Answer)

Explanation: ### Explanation The correct answer is **D. Sildenafil**. **Mechanism of Action (The "Why"):** Sildenafil is a **Phosphodiesterase-5 (PDE-5) inhibitor**. It works by preventing the degradation of cyclic Guanosine Monophosphate (cGMP) in the corpus cavernosum, leading to smooth muscle relaxation and increased blood flow. It is used to treat erectile dysfunction and pulmonary arterial hypertension. It does **not** interfere with the synthesis, metabolism, or receptor binding of testosterone. **Analysis of Incorrect Options:** * **A. Spironolactone:** A potassium-sparing diuretic that also acts as a weak **androgen receptor antagonist** and inhibits steroidogenesis. It is often used clinically to treat hirsutism in women due to these anti-androgenic effects. * **B. Flutamide:** A potent, non-steroidal **pure androgen receptor antagonist**. It competes with testosterone and dihydrotestosterone (DHT) for binding sites. It is primarily used in the management of prostate cancer. * **C. Finasteride:** A **5-alpha-reductase inhibitor**. It prevents the conversion of testosterone into its more potent metabolite, Dihydrotestosterone (DHT). It is used for Benign Prostatic Hyperplasia (BPH) and male pattern baldness. **High-Yield Clinical Pearls for NEET-PG:** * **Anti-androgen Classifications:** * *Receptor Antagonists:* Flutamide, Bicalutamide, Spironolactone, Cyproterone. * *5-α Reductase Inhibitors:* Finasteride (Type II), Dutasteride (Type I & II). * *GnRH Analogues (Continuous):* Leuprolide, Goserelin (initially cause a "flare," then suppress testosterone). * **Side Effect Note:** Spironolactone can cause **gynecomastia** in men due to its anti-androgenic activity. * **Sildenafil Contraindication:** Never co-administer with **nitrates**, as it can cause life-threatening hypotension.

Question 83: Which of the following is not a GnRH agonist?

A. Leuprolide
B. Nafarelin
C. Ganirelix (Correct Answer)
D. Buserelin

Explanation: ### Explanation The correct answer is **Ganirelix**. **1. Understanding the Mechanism:** GnRH (Gonadotropin-Releasing Hormone) modulators are divided into two distinct classes based on their interaction with the GnRH receptor: * **GnRH Agonists:** These drugs initially cause a "flare" (surge in LH/FSH) followed by down-regulation and desensitization of receptors, leading to medical castration. * **GnRH Antagonists:** These drugs provide **immediate** suppression of gonadotropins by competitively blocking the GnRH receptor without any initial flare. **Ganirelix** (along with Cetrorelix and Degarelix) belongs to this class. **2. Analysis of Options:** * **Leuprolide (Option A):** A potent synthetic GnRH agonist used commonly in prostate cancer and endometriosis. * **Nafarelin (Option B):** A GnRH agonist typically administered as a nasal spray for central precocious puberty and endometriosis. * **Buserelin (Option D):** Another GnRH agonist used in the management of hormone-dependent tumors and IVF protocols. **3. NEET-PG High-Yield Pearls:** * **The "Relix" Rule:** Drugs ending in **"-relix"** (Ganirelix, Cetrorelix, Degarelix, Abarelix) are **Antagonists**. * **The "Relin" Rule:** Most drugs ending in **"-relin"** (Goserelin, Nafarelin, Buserelin, Triptorelin) are **Agonists** (Exception: Leuprolide). * **Clinical Use:** GnRH antagonists (Ganirelix) are preferred in IVF protocols to prevent premature LH surges because they act instantly and do not require the 7–10 day desensitization period needed by agonists. * **Side Effects:** Both classes cause symptoms of hypogonadism (hot flashes, decreased bone density). However, only agonists carry the risk of "tumor flare" in prostate cancer.

Question 84: Which drug, when taken by a patient, necessitates careful monitoring for hypoglycemia?

A. Chlorpropamide (Correct Answer)
B. Furosemide
C. Corticosteroids
D. Theophylline

Explanation: **Explanation:** **Chlorpropamide** is a first-generation **Sulfonylurea** used in the management of Type 2 Diabetes Mellitus. Its primary mechanism of action involves stimulating insulin release from pancreatic beta cells by closing ATP-sensitive potassium channels. **Why Chlorpropamide causes hypoglycemia:** Among all sulfonylureas, Chlorpropamide has an exceptionally **long half-life (approx. 36 hours)** and is excreted unchanged by the kidneys. This prolonged duration of action significantly increases the risk of severe, prolonged hypoglycemia, especially in elderly patients or those with renal impairment. Therefore, patients on this drug require vigilant monitoring. **Analysis of Incorrect Options:** * **Furosemide (Loop Diuretic):** This drug is more likely to cause **hyperglycemia** (by inhibiting insulin release and causing hypokalemia) and electrolyte imbalances (hypokalemia, hyponatremia). * **Corticosteroids:** These are classic "diabetogenic" drugs. They promote gluconeogenesis and decrease peripheral glucose uptake, leading to **hyperglycemia** (Steroid-induced diabetes). * **Theophylline:** A methylxanthine used in asthma; in toxic doses, it typically causes **hyperglycemia** due to increased catecholamine release. **NEET-PG High-Yield Pearls:** 1. **Disulfiram-like reaction:** Chlorpropamide is notorious for causing flushing when taken with alcohol. 2. **SIADH:** Chlorpropamide can induce the Syndrome of Inappropriate Antidiuretic Hormone secretion, leading to dilutional hyponatremia. 3. **Drug of Choice for Hypoglycemia:** For sulfonylurea-induced hypoglycemia refractory to glucose, **Octreotide** (a somatostatin analogue) is used to suppress further insulin release.

Question 85: What is Pegvisomant used to treat?

A. Dwarfism
B. Acromegaly (Correct Answer)
C. Cretinism
D. Protein energy malnutrition

Explanation: **Pegvisomant** is a genetically modified analogue of human growth hormone (GH) that acts as a highly selective **Growth Hormone Receptor Antagonist**. 1. **Why Acromegaly is correct:** Acromegaly is caused by excessive secretion of GH, usually due to a pituitary adenoma, leading to elevated Insulin-like Growth Factor-1 (IGF-1) levels [1]. Pegvisomant binds to the GH receptor but prevents the functional dimerization required for signal transduction. By blocking the peripheral action of GH, it effectively lowers serum IGF-1 levels, making it a potent treatment for patients who are resistant to or intolerant of somatostatin analogues (like Octreotide). 2. **Why the other options are incorrect:** * **Dwarfism:** This is caused by GH deficiency. Treatment requires **Somatropin** (recombinant GH) or **Mecasermin** (recombinant IGF-1), not an antagonist. * **Cretinism:** This refers to congenital hypothyroidism. It is treated with **Levothyroxine**. * **Protein Energy Malnutrition (PEM):** While GH levels may be high in PEM due to resistance, Pegvisomant has no therapeutic role here; management focuses on nutritional rehabilitation. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** It is a GH receptor antagonist (blocks the JAK2-STAT5 pathway). * **Monitoring:** Unlike Somatostatin analogues, Pegvisomant **does not shrink the pituitary tumor**. Therefore, serial MRI scans of the pituitary are mandatory. * **Side Effects:** Potential for liver enzyme elevation (monitor LFTs) and lipohypertrophy at the injection site. * **Biochemical Goal:** The primary goal of therapy is the normalization of **serum IGF-1 levels**, not GH levels (GH levels may actually rise during treatment due to loss of negative feedback).

Question 86: A drug primarily reduces the static component of urinary obstruction in benign prostatic hypertrophy and takes more than 3 months to exert its beneficial effect. Which of the following is this drug?

A. Tamsulosin
B. Terazosin
C. Finasteride (Correct Answer)
D. Amphetamine

Explanation: ### Explanation **Correct Answer: C. Finasteride** **Mechanism and Rationale:** Benign Prostatic Hyperplasia (BPH) involves two components of urinary obstruction: 1. **Static Component:** Caused by the actual enlargement (hypertrophy) of the prostatic tissue. 2. **Dynamic Component:** Caused by the increased tone of smooth muscles in the bladder neck and prostate. **Finasteride** is a **5-alpha reductase inhibitor**. It blocks the conversion of Testosterone to Dihydrotestosterone (DHT), the potent androgen responsible for prostatic growth. By reducing DHT levels, it leads to a gradual reduction in prostate volume (shrinking the gland). Because this involves physical regression of tissue, it targets the **static component** and requires **3 to 6 months** of continuous therapy to show significant clinical improvement. --- ### Why other options are incorrect: * **Tamsulosin & Terazosin (Options A & B):** These are **Alpha-1 blockers**. They relax the smooth muscle of the bladder neck and prostate, targeting the **dynamic component**. They provide **rapid symptomatic relief** (within days) but do not reduce the size of the prostate. Tamsulosin is uroselective ($\alpha_{1A}$), whereas Terazosin is non-selective and can cause hypotension. * **Amphetamine (Option D):** This is a sympathomimetic stimulant. It has no role in BPH treatment and may actually worsen urinary retention by stimulating alpha-receptors in the bladder neck. --- ### High-Yield Clinical Pearls for NEET-PG: * **Finasteride vs. Dutasteride:** Finasteride inhibits Type II 5-alpha reductase; Dutasteride inhibits both Type I and Type II. * **PSA Levels:** 5-alpha reductase inhibitors can reduce Serum PSA levels by approximately 50%. This must be accounted for when screening for prostate cancer. * **Adverse Effects:** Finasteride is associated with erectile dysfunction, decreased libido, and gynecomastia. * **Drug of Choice:** For immediate relief, Alpha-blockers are preferred. For long-term reduction of prostate size and to prevent the need for surgery, 5-alpha reductase inhibitors are used. Combination therapy is often most effective.

Question 87: Bromocriptine inhibits which hormone?

A. Prolactin (Correct Answer)
B. Vasopressin
C. Imipramine
D. Levodopa

Explanation: **Explanation:** **Mechanism of Action:** Bromocriptine is a potent **Dopamine (D2) receptor agonist**. In the physiological regulation of the anterior pituitary, dopamine acts as the primary **Prolactin-Inhibiting Hormone (PIH)**. By stimulating D2 receptors on the lactotroph cells, Bromocriptine directly suppresses the synthesis and secretion of **Prolactin** [1, 2]. This makes it the first-line treatment for prolactinomas and hyperprolactinemia [2]. **Analysis of Options:** * **A. Prolactin (Correct):** As a dopamine agonist, Bromocriptine mimics the inhibitory effect of dopamine on prolactin release [2]. * **B. Vasopressin (Incorrect):** Vasopressin (ADH) is synthesized in the hypothalamus and released by the posterior pituitary. Its secretion is primarily regulated by plasma osmolality, not by D2 receptor agonists. * **C. Imipramine (Incorrect):** Imipramine is a Tricyclic Antidepressant (TCA). It is a drug, not a hormone, and its mechanism involves inhibiting the reuptake of Norepinephrine and Serotonin. * **D. Levodopa (Incorrect):** Levodopa is a precursor to dopamine used in Parkinson’s disease. While Bromocriptine and Levodopa are both used in Parkinsonism, Bromocriptine does not inhibit Levodopa; rather, they both aim to increase dopaminergic activity. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** While Bromocriptine is a classic answer, **Cabergoline** is now preferred for hyperprolactinemia due to its higher efficacy, longer half-life (twice-weekly dosing), and better side-effect profile [1]. * **Other Uses:** Bromocriptine is also used in **Acromegaly** (where it paradoxically decreases Growth Hormone) and **Parkinson’s Disease** [1]. * **Specific Side Effect:** Ergot-derived dopamine agonists like Bromocriptine are associated with **digital vasospasm** and **pulmonary/cardiac fibrosis** with long-term high-dose use.

Question 88: Which drug(s) can cause SIADH?

A. Chlorpropamide
B. Oxytocin
C. Cyclophosphamide
D. All of the above (Correct Answer)

Explanation: The Syndrome of Inappropriate Antidiuretic Hormone (SIADH) is characterized by the excessive release of ADH (Vasopressin), leading to water retention, dilutional hyponatremia, and concentrated urine [1]. Several drugs can induce this condition by either stimulating the release of ADH from the posterior pituitary or by sensitizing the renal tubules to its effects. **Breakdown of Options:** * **Chlorpropamide (Option A):** This first-generation sulfonylurea is a classic cause of SIADH [1]. It acts by increasing the sensitivity of the V2 receptors in the renal collecting ducts to endogenous ADH and also stimulates ADH release [1]. * **Oxytocin (Option B):** Oxytocin is structurally very similar to ADH (differing by only two amino acids) [2]. When administered in high doses (e.g., for labor induction or postpartum hemorrhage), it exerts a "cross-reactivity" effect on V2 receptors, leading to potent antidiuretic activity and potential water intoxication [2]. * **Cyclophosphamide (Option C):** This alkylating cytotoxic agent can cause SIADH, particularly when administered intravenously. It is often given with aggressive hydration to prevent hemorrhagic cystitis; if SIADH occurs simultaneously, it significantly increases the risk of severe hyponatremia. **Clinical Pearls for NEET-PG:** * **Other High-Yield Drugs causing SIADH:** SSRIs (e.g., Fluoxetine), Carbamazepine [1], Vincristine, and Haloperidol. * **Treatment of Choice:** Fluid restriction is the first-line management [1]. For pharmacological intervention, **Vaptans** (Tolvaptan, Conivaptan) are used as ADH receptor antagonists [1]. * **Demeclocycline:** An older tetracycline used to treat chronic SIADH because it induces a state of nephrogenic diabetes insipidus [1].

Question 89: A 57-year-old lady presents with chief complaints of fatigue and a 5 kg weight gain in one month. She has a 10-year history of well-controlled hypothyroidism treated with L-thyroxine. Recently, she was started on an anti-arrhythmic drug for a cardiac condition, and her symptoms began after its initiation. What is the most likely anti-arrhythmic drug she was prescribed?

A. Lignocaine
B. Amiodarone (Correct Answer)
C. Procainamide
D. Verapamil

Explanation: **Explanation:** The patient is presenting with symptoms of **hypothyroidism** (fatigue, weight gain) despite being on stable L-thyroxine therapy. The temporal relationship between starting an anti-arrhythmic and the onset of symptoms points toward **Amiodarone**. **Why Amiodarone is the correct answer:** Amiodarone is a Class III anti-arrhythmic drug that is structurally unique because it contains approximately **37% iodine by weight**. It affects thyroid function through two primary mechanisms: 1. **Inhibition of 5’-deiodinase:** It blocks the peripheral conversion of T4 to the active T3. 2. **Wolff-Chaikoff Effect:** The high iodine content can lead to a transient or sustained inhibition of thyroid hormone synthesis. In patients with pre-existing thyroid disease (like this patient with a 10-year history), the thyroid may fail to "escape" this effect, leading to **Amiodarone-Induced Hypothyroidism (AIH)**. **Why other options are incorrect:** * **Lignocaine (Class Ib):** Primarily a sodium channel blocker used for ventricular arrhythmias; it has no effect on iodine metabolism or thyroid function. * **Procainamide (Class Ia):** Known for causing Drug-Induced Lupus Erythematosus (DILE), but it does not interfere with the thyroid axis. * **Verapamil (Class IV):** A calcium channel blocker used for supraventricular tachycardia; it does not impact thyroid hormone levels. **NEET-PG High-Yield Pearls:** * **Amiodarone-Induced Thyrotoxicosis (AIT):** Amiodarone can also cause hyperthyroidism via Type 1 (excess iodine substrate) or Type 2 (destructive thyroiditis). * **Half-life:** Amiodarone has an exceptionally long half-life (~weeks to months) due to its high lipid solubility. * **Monitoring:** Patients on Amiodarone require baseline and periodic **Thyroid Function Tests (TFTs)** and **Liver Function Tests (LFTs)**, along with monitoring for pulmonary fibrosis and corneal microdeposits.

Question 90: Which Dipeptidyl Peptidase-4 (DPP4) inhibitor requires dose reduction in both liver and kidney failure?

A. Linagliptin
B. Sitagliptin
C. Saxagliptin
D. Vildagliptin (Correct Answer)

Explanation: ### Explanation The correct answer is **Vildagliptin**. **1. Why Vildagliptin is correct:** Vildagliptin is unique among DPP-4 inhibitors because it undergoes extensive metabolism in the liver (via hydrolysis) and its metabolites are primarily excreted by the kidneys. * **Renal Impairment:** In moderate to severe renal failure, the clearance of Vildagliptin is reduced, necessitating a dose reduction (typically to 50 mg once daily). * **Hepatic Impairment:** It is contraindicated in patients with hepatic impairment (including those with pre-treatment ALT or AST >3x ULN) because it has been associated with rare cases of hepatotoxicity. Therefore, it requires caution and dose adjustment/avoidance in liver dysfunction. **2. Why the other options are incorrect:** * **Linagliptin:** This is the "exception" drug in the class. It is primarily excreted via the **enterohepatic route (bile/feces)**. It does **not** require dose adjustment in either renal or hepatic failure, making it the safest choice for patients with chronic kidney disease (CKD). * **Sitagliptin:** It is primarily excreted unchanged in the urine. While it requires significant dose reduction in **renal failure**, no dose adjustment is necessary for hepatic impairment. * **Saxagliptin:** Similar to Sitagliptin, it requires dose adjustment in **renal failure**. While it is metabolized by CYP3A4/5, it generally does not require dose adjustment in mild-to-moderate hepatic impairment (though caution is advised in severe cases). **3. High-Yield Clinical Pearls for NEET-PG:** * **Linagliptin:** Highest potency and no renal dose adjustment (Mnemonic: **L**inagliptin = **L**eaves via **L**iver/Bile). * **Saxagliptin:** Associated with an increased risk of **hospitalization for heart failure** (SAVOR-TIMI 53 trial). * **DPP-4 Inhibitors (Gliptins):** They are weight-neutral and carry a low risk of hypoglycemia. * **Side Effects:** Most common are nasopharyngitis, upper respiratory tract infections, and rare risks of pancreatitis or joint pain.

Practice by Chapter

Hypothalamic and Pituitary Hormones

Practice Questions

Thyroid Drugs and Antithyroid Agents

Practice Questions

Insulin and Oral Hypoglycemic Agents

Practice Questions

Adrenocorticosteroids

Practice Questions

Sex Hormones: Estrogens and Progestins

Practice Questions

Androgens and Anabolic Steroids

Practice Questions

Hormonal Contraceptives

Practice Questions

Drugs Affecting Calcium Metabolism

Practice Questions

Drugs for Osteoporosis

Practice Questions

Pharmacological Management of Obesity

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free